Structure via PubChem · Public domain (PubChem)
(RS)-darglitazone
Sign in to saveAlso known as darglitazone
Darglitazone (previously known as CP 86325-2) is a member of the thiazolidinedione class of drugs and an agonist of peroxisome proliferator-activated receptor-γ (PPAR-γ), an orphan member of the nuclear receptor superfamily of transcription factors. It has a variety of insulin-sensitizing effects, such as improving glycemic and lipidemic control, and was researched by Pfizer as a treatment of metabolic disorders such as type 2 diabetes mellitus.
In the Vinony graph
Within Vinony's link graph, (RS)-darglitazone is referenced by 186 other articles, and connects out to metformin, alogliptin and anti-diabetic medication.
It sits within the topics Abandoned drugs, Chemical pages without DrugBank identifier and Drugboxes which contain changes to verified fields.
Its subject is documented across 6 Wikipedia language editions.
Chemical data
- Formula
- C23H20N2O4S
- Molecular weight
- 420.5 g/mol
- IUPAC name
- 5-[[4-[3-(5-methyl-2-phenyl-1,3-oxazol-4-yl)propanoyl]phenyl]methyl]-1,3-thiazolidine-2,4-dione
- SMILES
- CC1=C(N=C(O1)C2=CC=CC=C2)CCC(=O)C3=CC=C(C=C3)CC4C(=O)NC(=O)S4
- InChIKey
- QQKNSPHAFATFNQ-UHFFFAOYSA-N
- XLogP
- 4.1
- Polar surface area
- 115 Ų
- H-bond donors
- 1
- H-bond acceptors
- 6
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Phase 2
- Molecule type
- Small molecule
via ChEMBL · EBI
Wikidata facts
- Subclass of
- glitazone
- Mass
- 420.114
Show 3 more facts
- chemical formula
- C₂₃H₂₀N₂O₄S
- canonical SMILES
- CC1=C(N=C(O1)C2=CC=CC=C2)CCC(=O)C3=CC=C(C=C3)CC4C(=O)NC(=O)S4
- Commons category
- Darglitazone
Sources (2)
via Wikidata · CC0
~1 min read
Encyclopedic overview
2 sectionsContents
- Synthesis
- References
Darglitazone (previously known as CP 86325-2) is a member of the thiazolidinedione class of drugs and an agonist of peroxisome proliferator-activated receptor-γ (PPAR-γ), an orphan member of the nuclear receptor superfamily of transcription factors. It has a variety of insulin-sensitizing effects, such as improving glycemic and lipidemic control, and was researched by Pfizer as a treatment of metabolic disorders such as type 2 diabetes mellitus.
Its development was terminated on November 08, 1999.
Excerpted from Wikipedia’s “(RS)-darglitazone” article, available under the CC BY-SA 4.0 licence.